Lu-177 DOTATATE vs Everolimus in Lung NETs
Randomized Phase II Trial of Lutetium Lu-177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors
DRUG/TREATMENT: LUTETIUM LU-177 DOTATATE (PRRT) + (EVEROLIMUS)
CLINICALTRIALS.GOV IDENTIFIER: NCT04665739
SPONSOR: National Cancer Institute (NCI)
Dr. Suki Padda Discusses Lu177 Dotatate in Lung NETs
Dr. Heloisa Soares Discusses Lu-177 Dotatate in Lung NETs
This phase II trial studies the effect of lutetium Lu-177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in the body (advanced). Radioactive drugs, such as lutetium Lu-177 dotatate, may carry radiation directly to tumor cells and may reduce harm to normal cells. Lutetium Lu-177 dotatate may be more effective than everolimus in shrinking or stabilizing advanced bronchial neuroendocrine tumors.
Thomas A. Hope, MD, UCSF
Sukhmani K. Padda, MD, Cedars Sinai Medical Center, Los Angeles, California
This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.